An Open-Label Surgical Window of Opportunity Study Evaluating Pharmacodynamic Response of Orally Administered BAY 2402234 in Subjects With Recurrent Glioma, IDH Mutant, Grade 3 or 4
Latest Information Update: 14 Jan 2022
At a glance
- Drugs Orludodstat (Primary)
- Indications Astrocytoma; Glioma
- Focus Biomarker; Pharmacodynamics
- 17 Dec 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 01 Oct 2021 New trial record